<DOC>
	<DOCNO>NCT00230581</DOCNO>
	<brief_summary>In study , female patient IBS-d treat 8 week assess safety effectiveness DDP225 GI transit reduce IBS symptom .</brief_summary>
	<brief_title>8 Weeks Treatment With DDP225 Patients With Diarrhea Predominant IBS</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , multicenter study design ass safety efficacy DDP225 patient IBS-d . Female patient 18 65 year age history IBS-d least 6 month potentially eligible entry study . A total 88 eligible patient IBS-d study . The total duration study participation individual patient approximately 10 week ( 74 day ) initial screen visit final study evaluation . The total duration dose study medication ( either DDP225 placebo ) 8 week . Patients satisfy inclusion criterion none exclusion criterion eligible enter Treatment Period randomly assign one four treatment group . After patient randomized enters Treatment Period , take appropriate study medication day 56 day return clinic two week interval total four visit Treatment Period . During Treatment Period , patient maintain daily diary complete questionnaire . One week complete 56-day Treatment Period , patient return clinic final safety evaluation include physical examination , electrocardiogram , clinical laboratory testing .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Female patient 18 65 year age , inclusive . 2 . History IBSd least 6 month prior initial screen visit . 3 . Endoscopic/radiologic bowel evaluation rule cancer , obstruction , structural disease . 4 . The patient must complete least six day assessment patient diary one week period prior second screen visit . 5 . Negative serum urine pregnancy test postpartum least one year breast feed initial screen visit throughout study . For patient able bear child , acceptable method birth control must use throughout study . Patients unable bear child must documentation case report form ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . 6 . Able provide voluntary , write informed consent comprehension aspects protocol . 1 . Serious underlying disease , include psychiatric disorder current history condition affect bowel transit include biochemical structural abnormality , GI surgery 2 . Clinically significant abnormal examination finding laboratory test 3 . Inability stop take certain medication , plan change medication ( include herbal remedy ) could interfere study assessment 4 . Use drug ethanol may interfere compliance study procedure influence study outcome 5 . Presence medical condition could interfere interpretation study data 6 . Significant use nicotine caffeine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>IBS-d , IBS</keyword>
</DOC>